Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie dopęcherzowego systemu podawania erdafitynibu w miejscowym raku pęcherza moczowego

2 listopada 2026 zaktualizowane przez: Janssen Research & Development, LLC

Badanie fazy 1 dotyczące dopęcherzowego systemu podawania erdafitynibu (TAR-210) u uczestników z nieinwazyjnym lub naciekającym mięśnie rakiem pęcherza moczowego i wybranymi mutacjami lub fuzjami genu FGFR

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Szczegółowy opis

Bladder cancer is one of the most common malignancy worldwide, and non-muscle invasive (NMIBC) requires intensive regimens of frequent monitoring and local resection (transurethral resection of bladder [TURBT]). This study enrolls participants with non-muscle invasive or muscle invasive bladder cancer with activating fibroblast growth factor receptor (FGFR) mutations or fusions. Erdafitinib is a pan-FGFR inhibitor with demonstrated clinical activity when administered orally in patients with solid tumors, including bladder cancer, with FGFR genetic alterations. The Erdafitinib intravesical delivery system is designed to provide release of Erdafitinib in the bladder to treat localized bladder cancer, while reducing systemic toxicities. The study consists of a screening phase, a treatment phase, and a follow-up phase. Total duration of the study is approximately up to 7 years 4 months.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

235

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Hiszpania
      • Barcelona, Hiszpania, 08025
        • Fund. Puigvert
      • Barcelona, Hiszpania, 08036
        • Hosp Clinic de Barcelona
      • Barcelona, Hiszpania, 08035
        • Hosp Univ Vall D Hebron
      • Córdoba, Hiszpania, 14004
        • Hosp Reina Sofia
      • Madrid, Hiszpania, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Hiszpania, 28046
        • Hosp. Univ. La Paz
      • Madrid, Hiszpania, 28040
        • Hosp Univ Fund Jimenez Diaz
      • Valencia, Hiszpania, 46009
        • Instituto Valenciano de Oncologia
  • Holandia
      • Nijmegen, Holandia, 6525 GA
        • Radboud Umcn
      • Utrecht, Holandia, 3584 CX
        • UMC Utrecht
  • Izrael
      • Haifa, Izrael, 3109601
        • Rambam Medical Center
      • Haifa, Izrael, 3436212
        • Carmel Medical Center
      • Petah Tikva, Izrael, 4941492
        • Rabin Medical Center
      • Tel Aviv, Izrael, 64239
        • Tel Aviv Sourasky Medical Center
  • Japonia
      • Fukuoka, Japonia, 810 8563
        • National Hospital Organization Kyushu Medical Center
      • Kofu, Japonia, 400-8506
        • Yamanashi Prefectural Central Hospital
      • Osaka, Japonia, 558-8558
        • Osaka General Medical Center
      • Toyama, Japonia, 930 0194
        • Toyama University Hospital
  • Kanada
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Vancouver Prostate Centre Diamond Health Care Centre
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
        • Nova Scotia Health Authority
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 4A6
        • St Josephs Healthcare Hamilton
      • Toronto, Ontario, Kanada, M5G 2M9
        • Princess Margaret Cancer Centre
  • Korea Południowa
      • Goyang-si, Korea Południowa, 10408
        • National Cancer Center
      • Gwangju, Korea Południowa, 61469
        • Chonnam National University Hospital
      • Seoul, Korea Południowa, 03080
        • Seoul National University Hospital
      • Seoul, Korea Południowa, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Korea Południowa, 06591
        • The Catholic University of Korea Seoul St Marys Hospital
  • Niemcy
      • Dresden, Niemcy, 01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Duisburg, Niemcy, 47169
        • Urologicum Duisburg
      • Frankfurt am Main, Niemcy, 60590
        • Universitatsklinikum Frankfurt
      • Herne, Niemcy, 44625
        • Marien hospital Herne
      • Mettmann, Niemcy, 40822
        • Urologie Neandertal Praxis Mettmann
      • Münster, Niemcy, 48149
        • Universitatsklinikum Munster
      • Ulm, Niemcy, 89081
        • Universitaetsklinikum Ulm
  • Stany Zjednoczone
    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35294
        • University of Alabama at Birmingham - The Kirklin Clinic
    • California
      • Los Angeles, California, Stany Zjednoczone, 90033
        • University of Southern California
    • Colorado
      • Lone Tree, Colorado, Stany Zjednoczone, 80124
        • Urology Associates of Denver
    • Florida
      • Hialeah, Florida, Stany Zjednoczone, 33016
        • Urological Research Network
      • Largo, Florida, Stany Zjednoczone, 33771
        • Advanced Urology Institute
      • Orlando, Florida, Stany Zjednoczone, 32804
        • Advent Health Orlando
      • Oxford, Florida, Stany Zjednoczone, 34484
        • Advanced Urology Institute 1
      • Tampa, Florida, Stany Zjednoczone, 33612
        • H Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Northwestern University
      • Chicago Ridge, Illinois, Stany Zjednoczone, 60415
        • Associated Urological Specialists
    • Indiana
      • Greenwood, Indiana, Stany Zjednoczone, 46143
        • Urology of Indiana
      • Merrillville, Indiana, Stany Zjednoczone, 46410
        • Urologic Specialists of Northwest Indiana
    • Kentucky
      • Lexington, Kentucky, Stany Zjednoczone, 40506
        • University of Kentucky
    • Louisiana
      • Lafayette, Louisiana, Stany Zjednoczone, 70508
        • Southern Urology LLC
    • Massachusetts
      • Plymouth, Massachusetts, Stany Zjednoczone, 02360
        • Greater Boston Urology
    • Missouri
      • St Louis, Missouri, Stany Zjednoczone, 63141
        • Specialty Clinical Research of St Louis
    • New Jersey
      • Hackensack, New Jersey, Stany Zjednoczone, 07601
        • Hackensack University Medical Center Urology
    • New York
      • Syracuse, New York, Stany Zjednoczone, 13210
        • Associated Medical Professionals
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28204
        • Levine Cancer Institute, Carolinas HealthCare System
    • Ohio
      • Gahanna, Ohio, Stany Zjednoczone, 43230
        • Central Ohio Urology Group
    • South Carolina
      • Myrtle Beach, South Carolina, Stany Zjednoczone, 29572
        • Carolina Urologic Research Center
      • North Charleston, South Carolina, Stany Zjednoczone, 29406
        • Low Country Urology Clinics
    • Tennessee
      • Nashville, Tennessee, Stany Zjednoczone, 37209
        • Urology Associates
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78745
        • Urology Austin
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • Urology San Antonio Research

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

Parts 1-3:

  • Muscle-invasive or recurrent, non-muscle-invasive urothelial carcinoma of the bladder
  • For selected Cohorts: Activating tumor pan-fibroblast growth factor receptor (FGFR) mutation or fusion, as determined by local or central testing, approved by the sponsor prior to the start of study treatment. Local tissue-based results (if already existing) from next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests performed in Clinical Laboratory Improvement Amendments (CLIA) -certified or equivalent laboratories, or results from commercially available PCR or NGS tests
  • Cohorts 1 and 2: Bacillus Calmette-Guérin (BCG) experienced, or participants with no BCG experience because BCG was not available as a treatment option in the participant's location within the previous 2 years and is currently unavailable. Participants who received an abbreviated course of BCG due to toxicity are still eligible
  • Cohort 1 only: Refuses or is not eligible for radical cystectomy (RC)
  • Cohorts 2 and 4: Willing and eligible for RC

Part 4:

  • Have histologically confirmed diagnosis of recurrent Intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC) Ta LG tumors
  • Must not have undergone tumor debulking or selective ablation of visible lesions; partial tumor biopsy to confirm diagnosis and provide tissue for biomarker testing is permitted as long as remaining tumor is at least 5 millimeter (mm) in size
  • Must submit tissue and urine for FGFR testing
  • Can have a prior or concurrent second malignancy which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment

Exclusion Criteria:

Parts 1-3:

  • Concurrent extra-vesical (that is, urethra, ureter, renal pelvis) transitional cell carcinoma of the urothelium
  • Prior treatment with an pan-fibroblast growth factor receptor (FGFR) inhibitor
  • Received pelvic radiotherapy <=6 months prior to the planned start of study treatment. If received pelvic radiotherapy greater than (>)6 months prior to the start of study treatment, there must be no cystoscopic evidence of radiation cystitis
  • Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe use of Erdafitinib intravesical delivery system
  • Indwelling urinary catheter. Intermittent catheterization is acceptable

Part 4:

  • Histologically confirmed diagnosis of T1 NMIBC, HR NMIBC (HG/G2 or HG/G3 or CIS) or MIBC, locally advanced, non-resectable, or metastatic urothelial carcinoma at any time prior to enrollment. Previous high grade (HG) disease is accepted as long as diagnosis date is greater than or equal to (>=5) years ago and there is documentation of low grade (LG) Ta thereafter
  • Known allergies, hypersensitivity, or intolerance to any study component or its excipients
  • Has a current diagnosis of newly diagnosed IR-NMIBC
  • Received an investigational treatment for bladder cancer after Transurethral Resection of the Bladder Tumor (TURBT) for the current NMIBC diagnosis or within 4 weeks or the agent/therapy washout period, whichever is longer, before the planned first dose of study treatment, or is currently enrolled in an investigational study
  • Evidence of current bladder perforation by cystoscopy or imaging

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nielosowe
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Part 1: Dose Escalation

Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2.
Lek: Erdafitinib Intravesical Delivery System

Erdafitinib intravesical delivery system will be administered.

Inne nazwy:
  • JNJ-42756493
Eksperymentalny: Part 2: Dose Expansion

Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1.
Lek: Erdafitinib Intravesical Delivery System

Erdafitinib intravesical delivery system will be administered.

Inne nazwy:
  • JNJ-42756493
Eksperymentalny: Part 3: RP2D Dose Expansion

Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity.
Lek: Erdafitinib Intravesical Delivery System

Erdafitinib intravesical delivery system will be administered.

Inne nazwy:
  • JNJ-42756493
Eksperymentalny: Part 4: Phase 2 Expansion

Participants with recurrent IR-NMIBC will be enrolled in this part to further evaluate the safety, efficacy, and PK of the selected RP2D.
Lek: Erdafitinib Intravesical Delivery System

Erdafitinib intravesical delivery system will be administered.

Inne nazwy:
  • JNJ-42756493

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Parts 1 to 3: Number of Participants with Adverse Events (AEs)
Ramy czasowe: Up to approximately 7 years 4 months

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Up to approximately 7 years 4 months
Parts 1 to 3: Number of Participants with AEs by Severity
Ramy czasowe: Up to approximately 7 years 4 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
Up to approximately 7 years 4 months
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
Ramy czasowe: Up to 28 days

Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.
Up to 28 days
Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
Ramy czasowe: Up to approximately 7 years 4 months

Overall CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy.
Up to approximately 7 years 4 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Parts 1 to 3: Plasma Concentration of Erdafitinib
Ramy czasowe: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks

Plasma concentration of Erdafitinib will be reported.
Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
Parts 1 to 3: Urine Concentration of Erdafitinib
Ramy czasowe: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks

Urine concentration of Erdafitinib will be reported.
Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
Parts 1 to 3: Cohorts 1 and 2: Recurrence-Free Survival (RFS)
Ramy czasowe: Up to approximately 7 years 4 months

RFS is defined as the time from start of treatment to the first detection of any new high-grade bladder cancer or upper tract urothelial carcinoma or positive urine cytology.
Up to approximately 7 years 4 months
Parts 1 to 3: Cohort 3 and 5: Complete Response (CR) Rate
Ramy czasowe: At 3 months

CR is defined as the absence of urothelial carcinoma by cystoscopy, confirmed pathologically at first assessment, and negative urine cytology.
At 3 months
Parts 1 to 3: Cohort 3 and 5: Duration of CR
Ramy czasowe: Up to approximately 7 years 4 months

Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first.
Up to approximately 7 years 4 months
Parts 1 to 3: Cohort 4: Pathological Complete Response (pCR) Rate
Ramy czasowe: Up to 8 weeks

pCR rate is defined as percentage of participants with no pathologic evidence of intravesical disease (pT0) and no pathologic evidence of nodal involvement (pN0).
Up to 8 weeks
Parts 1 to 3: Cohort 4: No Pathologic Evidence of Intravesical Disease (pT0)
Ramy czasowe: Up to 8 weeks

pT0 rate is defined as percentage of participants with no Pathologic Evidence of Intravesical Disease.
Up to 8 weeks
Parts 1 to 3: Cohort 4: Rate of downstaging to Less than (<) pT2
Ramy czasowe: Up to 8 weeks

Rate of downstaging to <pT2 is defined as percentage of participants with pT stage <2.
Up to 8 weeks
Part 4: Duration of CR (DoCR) in Participants with IR-NMIBC
Ramy czasowe: Up to approximately 7 years 4 months

Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first.
Up to approximately 7 years 4 months
Part 4: Complete Response (CR) at 3 Months in Participants with IR-NMIBC
Ramy czasowe: At Month 3

CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy at the first disease evaluation.
At Month 3
Part 4: Transurethral Resection of the Bladder Tumor (TURBT)-Free Survival in Participants With IR-NMIBC
Ramy czasowe: Up to approximately 7 years 4 months

Participants with TURBT-free survival will be reported.
Up to approximately 7 years 4 months
Part 4: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) by Severity
Ramy czasowe: Up to approximately 7 years 4 months

TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline. Severity was assessed using National cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity grades ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
Up to approximately 7 years 4 months
Part 4: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score
Ramy czasowe: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
Part 4: Change from Baseline in European Organization for the Research and Treatment of Cancer Non-Muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC 24) Score
Ramy czasowe: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-C30 Scores
Ramy czasowe: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-NMIBC24 Scores
Ramy czasowe: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Janssen Research & Development, LLC

Śledczy

  • Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

11 kwietnia 2022

Zakończenie podstawowe (Szacowany)

30 marca 2028

Ukończenie studiów (Szacowany)

24 lipca 2029

Daty rejestracji na studia

Pierwszy przesłany

30 marca 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

30 marca 2022

Pierwszy wysłany (Rzeczywisty)

7 kwietnia 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • CR109115
  • 42756493BLC1003 (Inny identyfikator: Janssen Research & Development, LLC)
  • 2021-004144-22 (Numer EudraCT)
  • 2023-506265-65-00 (Identyfikator rejestru: EUCT number)
  • 2023 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj